New York, NY—IFF announced that it has entered into an agreement to acquire Health Wright Products, LLC (HWP). The acquisition will bring formulation and finished format capabilities to IFF’s Health & Biosciences probiotics, natural extracts and botanicals businesses, according to a press release, allowing for innovation in custom formulation and combination products through joint capabilities.

Founded in 1995, HWP is a leader in formulation and capsule manufacturing for the dietary supplement industry. The privately-owned company is a long-time business partner of IFF’s Health & Biosciences probiotics business, IFF shared, adding that HWP manufactures custom formulations and delivers encapsulation and packaging to meet the industry's more exacting requirements for probiotic products.

With more than 165,000 ft2of manufacturing space, HWP generated approximately $100 million in annual revenue in 2021, IFF reported. HWP employs over 225 people, and these employees will continue with the company after the sale.

“Today’s announcement is driven by our commitment to enhance long-term value to our partners and customers,” said Simon Herriott, President, IFF’s Health & Biosciences division, in the release. "Producing thousands of unique and complex formulations for the industry’s most trusted brands, Health Wright Products formulation and finished format abilities will allow us to develop new and customized solutions and formats for a broad base of customers."

Mark Wright, President, Health Wright Products, added, “We look forward to joining IFF’s Health & Biosciences division. Health Wright Products best-in-class quality manufacturing and formulation capabilities, combined with the strong biotech innovation pipeline of IFF’s Health & Biosciences, is an exciting proposition for our customers and employees."
Related: IFF Ingredient Shown to Improve Brain Activity IFF Resource Hub Offers Microbiome Innovation Resources
IFF noted that the sale is expected to close in the first quarter of 2022, subject to customary closing conditions, and regulatory clearances. Financial terms of the deal have not been disclosed.